Sarepta Therapeutics Overview
- Year Founded
-
1980
- Status
-
Public
- Employees
-
1,372
- Stock Symbol
-
SRPT
- Investments
-
12
- Share Price
-
$101.35
- (As of Monday Closing)
Sarepta Therapeutics General Information
Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Contact Information
Website
www.sarepta.comCorporate Office
- 215 First Street
- Cambridge, MA 02142
- United States
Corporate Office
- 215 First Street
- Cambridge, MA 02142
- United States
Sarepta Therapeutics Stock Performance
As of 17-Mar-2025, Sarepta Therapeutics’s stock price is $101.35. Its current market cap is $9.8B with 97M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $101.35 | $97.19 | $97.06 - $173.25 | $9.8B | 97M | 879K | $2.34 |
Sarepta Therapeutics Financials Summary
As of 31-Dec-2024, Sarepta Therapeutics has a trailing 12-month revenue of $1.9B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 11,813,414 | 11,813,414 | 8,658,671 | 10,880,381 |
| Revenue | 1,901,979 | 1,901,979 | 1,243,336 | 933,013 |
| EBITDA | 245,122 | 245,122 | (539,660) | (622,574) |
| Net Income | 235,239 | 235,239 | (535,977) | (703,488) |
| Total Assets | 3,963,173 | 3,963,173 | 3,264,576 | 3,128,366 |
| Total Debt | 1,343,070 | 1,343,070 | 1,396,808 | 1,617,359 |
Sarepta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sarepta Therapeutics Comparisons
Industry
Financing
Details
Sarepta Therapeutics Competitors (32)
One of Sarepta Therapeutics’s 32 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Ultragenyx Pharmaceutical | Formerly VC-backed | Novato, CA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Nanoviricides | Corporation | Shelton, CT |
Sarepta Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sarepta Therapeutics Patents
Sarepta Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250066776-A1 | Antisense oligomers for treatment of chronic kidney disease | Pending | 27-Apr-2023 | ||
| US-20240218365-A1 | Formulation of an antisense oligomer conjugate | Pending | 02-Nov-2022 | ||
| AU-2023299274-A1 | Methods of treating muscular dystrophy | Pending | 30-Jun-2022 | ||
| AU-2023235302-A1 | Phosphorodiamidate morpholino oligomer conjugates | Pending | 17-Mar-2022 | ||
| EP-4493693-A1 | Phosphorodiamidate morpholino oligomer conjugates | Pending | 17-Mar-2022 | C12N15/113 |
Sarepta Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sarepta Therapeutics Investments & Acquisitions (12)
Sarepta Therapeutics’s most recent deal was a Later Stage VC with Lexeo Therapeutics. The deal was made on 28-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Lexeo Therapeutics | 28-Aug-2023 | Later Stage VC | Biotechnology | ||
| StrideBio | 02-Jun-2022 | Later Stage VC | Drug Discovery | ||
| StrideBio | 11-Mar-2021 | Later Stage VC | Drug Discovery | ||
| AavantiBio | 22-Oct-2020 | Early Stage VC | Drug Discovery | ||
| Lysogene | 12-Mar-2020 | PIPE | Biotechnology |
Sarepta Therapeutics ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
29.95 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Sarepta Therapeutics Exits (4)
Sarepta Therapeutics’s most recent exit was on 02-Jun-2022 from StrideBio. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| StrideBio | 02-Jun-2022 | Completed |
|
||
| StrideBio | 11-Mar-2021 | Completed |
|
||
| AavantiBio | 22-Oct-2020 | Completed |
|
||
| Lysogene | 12-Mar-2020 | PIPE | Completed |
|
Sarepta Therapeutics FAQs
-
When was Sarepta Therapeutics founded?
Sarepta Therapeutics was founded in 1980.
-
Where is Sarepta Therapeutics headquartered?
Sarepta Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Sarepta Therapeutics?
Sarepta Therapeutics has 1,372 total employees.
-
What industry is Sarepta Therapeutics in?
Sarepta Therapeutics’s primary industry is Drug Discovery.
-
Is Sarepta Therapeutics a private or public company?
Sarepta Therapeutics is a Public company.
-
What is Sarepta Therapeutics’s stock symbol?
The ticker symbol for Sarepta Therapeutics is SRPT.
-
What is the current stock price of Sarepta Therapeutics?
As of 17-Mar-2025 the stock price of Sarepta Therapeutics is $101.35.
-
What is the current market cap of Sarepta Therapeutics?
The current market capitalization of Sarepta Therapeutics is $9.8B.
-
What is Sarepta Therapeutics’s current revenue?
The trailing twelve month revenue for Sarepta Therapeutics is $1.9B.
-
Who are Sarepta Therapeutics’s competitors?
Moderna, Ultragenyx Pharmaceutical, Intellia Therapeutics, Alnylam Pharmaceuticals, and Nanoviricides are some of the 32 competitors of Sarepta Therapeutics.
-
What is Sarepta Therapeutics’s annual earnings per share (EPS)?
Sarepta Therapeutics’s EPS for 12 months was $2.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
